161 related articles for article (PubMed ID: 36261902)
41. Efficacy of the Topical Calcineurin Inhibitors Tacrolimus and Pimecrolimus in the Treatment of Vitiligo in Infants Under 2 Years of Age: A Randomized, Open-Label Pilot Study.
Hu W; Xu Y; Ma Y; Lei J; Lin F; Xu AE
Clin Drug Investig; 2019 Dec; 39(12):1233-1238. PubMed ID: 31522334
[TBL] [Abstract][Full Text] [Related]
42. Overview of Safety, Efficacy, and Patient Counseling for Ruxolitinib in Treating Atopic Dermatitis.
Mancuso-Stewart E; Rodger J; Zirwas M
Skinmed; 2023; 21(1):40-43. PubMed ID: 36987827
[TBL] [Abstract][Full Text] [Related]
43. Topical pimecrolimus in the treatment of vitiligo.
Boone B; Ongenae K; Van Geel N; Vernijns S; De Keyser S; Naeyaert JM
Eur J Dermatol; 2007; 17(1):55-61. PubMed ID: 17324829
[TBL] [Abstract][Full Text] [Related]
44. Topical methotrexate 1% gel for treatment of vitiligo: A case report and review of the literature.
Abdelmaksoud A; Dave DD; Lotti T; Vestita M
Dermatol Ther; 2019 Sep; 32(5):e13013. PubMed ID: 31265164
[TBL] [Abstract][Full Text] [Related]
45. The use of Janus kinase inhibitors and narrowband ultraviolet B combination therapy in non-segmental vitiligo.
Yousefian F; Yadlapati S; Browning JC
J Cosmet Dermatol; 2023 Mar; 22(3):1105-1107. PubMed ID: 36440703
[TBL] [Abstract][Full Text] [Related]
46. Dermatologic Applications and Safety Considerations of Janus Kinase Inhibitors.
Svoboda SA; Johnson N; Phillips M
Skin Therapy Lett; 2020 Sep; 25(4):6-11. PubMed ID: 33017108
[TBL] [Abstract][Full Text] [Related]
47. Clinical outcomes of topical bimatoprost for nonsegmental facial vitiligo: A preliminary study.
Kanokrungsee S; Pruettivorawongse D; Rajatanavin N
J Cosmet Dermatol; 2021 Mar; 20(3):812-818. PubMed ID: 32744369
[TBL] [Abstract][Full Text] [Related]
48. Calcipotriene and corticosteroid combination therapy for vitiligo.
Travis LB; Silverberg NB
Pediatr Dermatol; 2004; 21(4):495-8. PubMed ID: 15283800
[TBL] [Abstract][Full Text] [Related]
49. Topical Janus kinase inhibitors: A review of applications in dermatology.
Hosking AM; Juhasz M; Mesinkovska NA
J Am Acad Dermatol; 2018 Sep; 79(3):535-544. PubMed ID: 29673776
[TBL] [Abstract][Full Text] [Related]
50. Trichomegaly induced by topical tacrolimus for the treatment of periorbital vitiligo: A brief report of a new adverse effect.
Molés-Poveda P; Cowen EW
Pediatr Dermatol; 2019 Jul; 36(4):e95-e96. PubMed ID: 31070265
[TBL] [Abstract][Full Text] [Related]
51. Topical treatment in vitiligo and the potential uses of new drug delivery systems.
Garg BJ; Saraswat A; Bhatia A; Katare OP
Indian J Dermatol Venereol Leprol; 2010; 76(3):231-8. PubMed ID: 20445292
[TBL] [Abstract][Full Text] [Related]
52. New treatment modalities for vitiligo: focus on topical immunomodulators.
Kostovic K; Pasic A
Drugs; 2005; 65(4):447-59. PubMed ID: 15733009
[TBL] [Abstract][Full Text] [Related]
53. Tofacitinib cream plus narrowband ultraviolet B phototherapy for segmental vitiligo in a child.
Olamiju B; Craiglow BG
Pediatr Dermatol; 2020 Jul; 37(4):754-755. PubMed ID: 32255214
[TBL] [Abstract][Full Text] [Related]
54. Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis.
Nakagawa H; Nemoto O; Igarashi A; Saeki H; Murata R; Kaino H; Nagata T
J Dermatol; 2020 Feb; 47(2):114-120. PubMed ID: 31820485
[TBL] [Abstract][Full Text] [Related]
55. Biologic and targeted therapeutics in vitiligo.
Karagaiah P; Schwartz RA; Lotti T; Wollina U; Grabbe S; Goldust M
J Cosmet Dermatol; 2023 Jan; 22(1):64-73. PubMed ID: 35029034
[TBL] [Abstract][Full Text] [Related]
56. A case of new-onset vitiligo in a patient on tofacitinib and brief review of paradoxical presentations with other novel targeted therapies.
Nguyen JK; Schlichte MJ; Jogi R; Alikhan M; Patel AB
Dermatol Online J; 2020 Mar; 26(3):. PubMed ID: 32609446
[TBL] [Abstract][Full Text] [Related]
57. Management of Alopecia Areata With Topical JAK Inhibitor Therapy: An Evidence-Based Review.
Abduelmula A; Mufti A; Mistry J; Sachdeva M; Beecker J; Prajapati VH; Yeung J
J Cutan Med Surg; 2023; 27(1):73-75. PubMed ID: 36189927
[No Abstract] [Full Text] [Related]
58. Janus kinase inhibitors for atopic dermatitis: a promising treatment modality.
Cartron AM; Nguyen TH; Roh YS; Kwatra MM; Kwatra SG
Clin Exp Dermatol; 2021 Jul; 46(5):820-824. PubMed ID: 33484582
[TBL] [Abstract][Full Text] [Related]
59. Topical melagenine for repigmentation in twenty-two child patients with vitiligo on the scalp.
Xu AE; Wei XD
Chin Med J (Engl); 2004 Feb; 117(2):199-201. PubMed ID: 14975202
[TBL] [Abstract][Full Text] [Related]
60. Vitiligo treated with topical clobetasol propionate.
Kumari J
Arch Dermatol; 1984 May; 120(5):631-5. PubMed ID: 6721525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
